/
CLGN
$0.37+$0.03 (+10.19%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$4.8M
14M shares
52-week range
$0.27 – $3.23
3% from low
Exchange
NASDAQ
CS
Borrow rate
18.89%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-20.80
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.8M | $2.3M | $6.1M | $15.6M | $299.0K | $11.0M | $515.0K | $2.4M |
| Cost of revenue | $1.9M | $1.9M | $3.5M | $2.0M | $1.5M | $3.1M | $2.7M | $1.7M |
| Gross profit | $3.1M | $439.0K | $2.7M | $13.6M | −$1.2M | $7.9M | −$2.1M | $624.0K |
| Gross margin | 65.0% | 18.9% | 43.7% | 87.2% | -393.6% | 71.8% | -417.1% | 26.3% |
| R&D | $5.2M | $4.4M | $3.7M | $7.6M | $10.3M | $10.5M | $10.5M | $8.2M |
| Operating income | −$4.1M | −$7.6M | −$5.6M | $65.0K | −$17.1M | −$7.5M | −$17.3M | −$11.5M |
| EBITDA | −$5.9M | −$10.6M | −$5.1M | $1.0M | −$15.8M | −$5.9M | −$15.6M | −$10.6M |
| Net income | −$6.2M | −$11.2M | −$5.8M | $237.0K | −$16.9M | −$7.0M | −$16.6M | −$11.5M |
| Net margin | -130.5% | -481.6% | -94.1% | 1.5% | -5660.5% | -64.0% | -3225.0% | -484.6% |
| EPS (diluted) | -1.43 | -2.95 | -0.84 | 0.03 | -1.52 | -0.62 | -1.45 | -0.94 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-0.59 | $-0.59–$-0.59 | 1 |
| 2027 | $3M | $-0.18 | $-0.18–$-0.18 | 1 |
| 2028 | $3M | $-0.17 | $-0.17–$-0.17 | 1 |
| 2029 | $4M | $-0.15 | $-0.15–$-0.15 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
CollPlant Biotechnologies Ltd Ordinary Shares
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
www.collplant.com- Employees
- 39
- IPO / List date
- Jun 4, 2021
Held by traders on TradeandTell
No one on the platform currently holds CLGN.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CLGN as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CLGN yet.
